RxDoctor Payments Data

Aaron Shumway, MD

Family Medicine · Yuma, AZNPI 1528627627

Payments from drug & device makers

$590in general payments, 2019–2025

Across 30 payments — averaging $19.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Idorsia Pharmaceuticals US Inc$176
  • Novo Nordisk$76
  • AstraZeneca$75
  • Pfizer$54
  • Antares Pharma, Inc.$40
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$39
  • plus $130 from 6 others

What the payments were for

  • Food & beverage$57097%
  • Entertainment$203%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$590 in reported general payments places this provider in the 60th percentile of 2,099 family medicine providers in Arizona.

See all family medicine providers in Arizona

Medicare billing

Part B allowed, 2024
$54,895
Medicare patients
178
Services billed
692

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide31$33,407
OzempicSemaglutide17$27,789
FarxigaDapagliflozin Propanediol15$17,933
JardianceEmpagliflozin20$17,512
TrulicityDulaglutide11$14,765
Tamsulosin Hcl109$1,538
Rosuvastatin Calcium113$1,259
Atorvastatin Calcium165$1,212
Lantus SolostarInsulin Glargine,hum.Rec.Anlog14$1,117
SynthroidLevothyroxine Sodium12$1,012
Bupropion XlBupropion Hcl32$777
Omeprazole40$776
Levothyroxine Sodium89$775
Amlodipine Besylate109$710
Pantoprazole Sodium48$635

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$76$27,78917 claims
AstraZenecaFarxiga$75$17,93315 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 2,099 family medicine providers in Arizona.

Other family medicine in Yuma

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →